03.12.15
Irvine, Calif.-based Endologix Inc. is on the hunt to replace its chief financial officer (CFO). Shelley Thunen has decided to resign from her position in order to spend more time with family and pursue other personal interests. She will continue to serve as the company’s chief financial officer through the recruitment and transition process to a new CFO and will remain available to the Endologix as long as required to ensure a smooth and complete transition.
“On behalf of the entire Endologix team, I would like to thank Shelley for her dedication and contributions to the growth of Endologix over the past few years,” said Chairman and CEO John McDermott. “During this time, we raised additional capital, expanded our global infrastructure, and continued to gain market share with our EVAR and EVAS platforms. I appreciate her commitment to the transition process and wish her the very best in her future endeavors.”
Endologix makes devices that treat aortic disorders.
“On behalf of the entire Endologix team, I would like to thank Shelley for her dedication and contributions to the growth of Endologix over the past few years,” said Chairman and CEO John McDermott. “During this time, we raised additional capital, expanded our global infrastructure, and continued to gain market share with our EVAR and EVAS platforms. I appreciate her commitment to the transition process and wish her the very best in her future endeavors.”
Endologix makes devices that treat aortic disorders.